The determination of raloxifene in rat tissue using HPLC
- 19 January 2007
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 21 (3), 229-233
- https://doi.org/10.1002/bmc.725
Abstract
We report a rapid and reliable HPLC‐UV method for determination of raloxifene, a kind of selective estrogen receptor modulator (SERM), in rat tissue. Proteins were precipitated by adding 200 µL of acetonitrile and 50 µL of methanol to 100 µL of the tissue homogenates, following vortex mixing and centrifugation. Separation was carried out on a reversed‐phase C18 column (150 × 4.6 mm, 5 µm) with a mobile phase of acetonitrile:0.05 m ammonium acetate (pH 4.0 ± 0.1; 33:67, v/v) at a flow rate of 1.0 mL/min. The UV detection wavelength was set at 289 nm and the temperature of column was kept at 23°C, without interference from endogenous tissue compounds. The calibration curve was linear from 0.0125 to 10.0 µg/mL with correlation coefficient of over 0.994, while the limit of quantification was 0.008 µg/mL. The intra‐ and inter‐day coefficients of variation were less than 10% (RSD). The recovery of assay was between 95.8 and 104.5%. Furthermore, the method was used to measure the concentration of raloxifene in rat tissue after a simple oral dose. The highest level was observed in liver, lung, spleen, then heart and kidney. The lowest level was found in brain. These results suggest that raloxifene distributes rapidly and moderately into tissues such as liver, lung and spleen. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 12 references indexed in Scilit:
- Raloxifene Reduces Fractures in Postmenopausal Women with OsteoporosisClinical Orthopaedics & Related Research, 2006
- Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6-Month Double-Blind Placebo-Controlled TrialJournal of Bone and Mineral Research, 2005
- HPLC analysis of raloxifene hydrochloride and its application to drug quality control studiesPharmacological Research, 2005
- Cardiovascular effects of raloxifene: the arterial and venous systemsAmerican Heart Journal, 2004
- Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 yearsMenopause, 2003
- Pharmacokinetics of Selective Estrogen Receptor ModulatorsClinical Pharmacokinetics, 2003
- Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical TrialJournal of Clinical Endocrinology & Metabolism, 2002
- Characterization of Raloxifene Glucuronidation in Vitro: Contribution of Intestinal Metabolism to Presystemic ClearanceDrug Metabolism and Disposition, 2002
- Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeysXenobiotica, 1984
- Short reviewsJournal of Baltic Studies, 1974